Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 150%
2 regions · 11 outlets · 15 reports — every source grouped by where each outlet is based. Region reflects only headquarters, not the subject of the report.
US
9 articles · 5 outlets
Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 150%
Merck and Moderna say cancer vaccine shows signs of preventing recurrence of melanoma
Moderna stock surges as melanoma vaccine trial shows "landmark moment
Merck and Moderna say cancer vaccine shows signs of preventing recurrence of melanoma
Moderna shares double as cancer vaccine data rekindles investor hopes
Merck and Moderna say melanoma vaccine shows promise
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Other
6 articles · 6 outlets
Personalized mRNA cancer vaccine shows promise in extending life span in melanoma trial
MRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for…
Promising Results for mRNA Cancer Vaccine from Moderna and Merck
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma